Accounts Receivable

3 Months Ended

Mar. 31, 2023

Receivables [Abstract]

Accounts Receivable

Accounts Receivable

The Company’s accounts receivable consists primarily of amounts due from third-party payors and patients. See Note 2 for a summary of the Company’s policies relating to accounts receivable and allowance for credit losses.

Accounts Receivable as of March 31, 2023 and December 31, 2022 consist of the following:

(in thousands)	March 31, 2023		December 31, 2022
Oral drug accounts receivable	$	6,418	$	4,165
Capitated accounts receivable	624		1,623
FFS accounts receivable	29,197		26,313
Clinical trials accounts receivable	2,662		2,443
Other trade receivables	7,055		5,272
Total	$	45,956	$	39,816

The Company adopted ASU 2016-13, as amended, effective January 1, 2023, and determined the allowance for credit losses was immaterial as of March 31, 2023. No allowance for credit losses was recorded as of March 31, 2023 and December 31, 2022.

During the three months ended March 31, 2023 and 2022, credit losses related to direct write-offs totaled $11 and $177, respectively. Credit losses were a result of accounts receivable on completed contracts that were deemed uncollectible during the period due to delayed collection efforts. During the three months ended March 31, 2023 and 2022, the Company had recoveries of credit losses of $10 and $23, respectively.